ICARES Medicus (6612) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 奈米醫材

ICARES Medicus (6612) reported revenue of NT$105.5 million for Oct 2026, +15.2% year on year and -4.9% from the previous month. Revenue for Jan–Oct 2026 was NT$1.11 billion (+20.8% year on year).

Year-on-year revenue growth: 9 months in a row. →

In Oct 2026, it ranked No. 70 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$84.9 million24/10Nov 2024 NT$97.6 millionDec 2024 NT$74.4 millionJan 2025 NT$89.4 millionFeb 2025 NT$105.5 million25/02Mar 2025 NT$102.7 millionApr 2025 NT$97.6 millionMay 2025 NT$82.5 millionJun 2025 NT$89.1 million25/06Jul 2025 NT$84 millionAug 2025 NT$98 millionSep 2025 NT$81.6 millionOct 2025 NT$91.6 million25/10Nov 2025 NT$95.1 millionDec 2025 NT$112.8 millionJan 2026 NT$75.4 millionFeb 2026 NT$113.1 million26/02Mar 2026 NT$110.1 millionApr 2026 NT$113.4 millionMay 2026 NT$118.2 millionJun 2026 NT$116.1 million26/06Jul 2026 NT$108.2 millionAug 2026 NT$142.8 millionSep 2026 NT$110.9 millionOct 2026 NT$105.5 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$105.5 million+15.2%-4.9%
Sep 2026NT$110.9 million+36.0%-22.3%
Aug 2026NT$142.8 million+45.7%+32.0%
Jul 2026NT$108.2 million+28.8%-6.8%
Jun 2026NT$116.1 million+30.2%-1.8%
May 2026NT$118.2 million+43.3%+4.2%
Apr 2026NT$113.4 million+16.2%+3.0%
Mar 2026NT$110.1 million+7.3%-2.6%
Feb 2026NT$113.1 million+7.1%+50.0%
Jan 2026NT$75.4 million-15.7%-33.2%
Dec 2025NT$112.8 million+51.6%+18.6%
Nov 2025NT$95.1 million-2.5%+3.8%
Oct 2025NT$91.6 million+7.8%+12.3%
Sep 2025NT$81.6 million+1.8%-16.8%
Aug 2025NT$98 million+0.2%+16.7%
Jul 2025NT$84 million+6.3%-5.8%
Jun 2025NT$89.1 million+28.9%+8.1%
May 2025NT$82.5 million+43.4%-15.5%
Apr 2025NT$97.6 million+67.5%-5.0%
Mar 2025NT$102.7 million+50.4%-2.7%
Feb 2025NT$105.5 million+119.7%+18.0%
Jan 2025NT$89.4 million+100.1%+20.2%
Dec 2024NT$74.4 million+105.9%-23.8%
Nov 2024NT$97.6 million+118.7%+14.9%
Oct 2024NT$84.9 million+44.5%+6.0%

Jan–Oct 2026 cumulative: NT$1.11 billion (+20.8% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: ICARES Medicus vs PEC / ICARES Medicus vs Lotus Pharm / ICARES Medicus vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16